Other
Zolmitriptan orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use
- Only use zolmitriptan if a clear diagnosis of migraine has been established. If a patient has no response to zolmitriptan treatment for the first migraine attack, reconsider the diagnosis of migraine before zolmitriptan is administered to treat any subsequent attacks.
- Zolmitriptan orally disintegrating tablets are not indicated for the prevention of migraine attacks.
- Safety and effectiveness of zolmitriptan have not been established for cluster headache.
- Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c oronary artery vasospasm including Prinzmetal's angina [seeWarnings and Precautions (5.1) ].
- Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [seeWarnings and Precautions (5.2) ].
- History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ].
- Peripheral vascular disease (PVD) [see Warnings and Precautions (5.5) ].
- Ischemic bowel disease [see Warnings and Precautions (5.5) ]
- Uncontrolled hypertension [seeWarnings and Precautions (5.8) ].
- Recent use (i.e., within 24 hours) of another 5-HT1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [seeDrug Interactions (7.1, 7.3) ].
- Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [seeDrug Interactions (7.2), Clinical Pharmacology (12.3) ].
- Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see Adverse Reactions (6.2) ].
- Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina [see Warnings and Precautions (5.1)].
- Arrthymias [see Warnings and Precautions (5.2)].
- Chest and or Throat, Neck and Jaw Pain/Tightness/Pressure [see Warnings and Precautions (5.3)].
- Cerebrovascular Events [see Warnings and Precautions (5.4)].
- Other Vasospasm Reactions [see Warnings and Precautions (5.5)].
- Medication Overuse Headache [see Warnings and Precautions (5.6)].
- Serotonin Syndrome [see Warnings and Precautions (5.7)].
- Increase in Blood Pressure [see Warnings and Precautions (5.8)].
- Risks in Patients with Phenylketonuria [see Warnings and Precautions (5.9)].
2.5 mg tablets are white/mottled white to cream white, round, flat-faced uncoated tablet, debossed with '715' on one side and plain on other the side.
5 mg tablets are white/mottled white to cream white round, biconvex, beveled, uncoated tablet, debossed with '717' on one side and plain on the other side.
Zolmitriptan orally disintegrating tablets are contraindicated in patients with:
The following adverse reactions are described elsewhere in other sections of the prescribing information:
Manufactured by:
Zydus Lifesciences Ltd.
Ahmedabad, India
Distributed by:
Zydus Pharmaceuticals (USA) Inc.
Pennington, NJ 08534
Rev.: 01/23